MIRM — Mirum Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.16bn
- $1.18bn
- $186.37m
- 27
- 15
- 66
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.65 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.28% | ||
| Return on Equity | -83.65% | ||
| Operating Margin | -84.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 19.14 | 77.06 | 186.37 | 316.93 | 422.49 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Directors
- Michael Grey CHM (68)
- Christopher Peetz PRE (42)
- Ian Clements CFO (52)
- Peter Radovich COO (43)
- Pamela Vig CSO (50)
- Lara Longpre OTH (51)
- Edwin Tucker OTH (49)
- Carol Brosgart DRC (70)
- William Fairey DRC (56)
- Laura Brege IND (63)
- Laurent Fischer IND (57)
- Patrick Heron IND (51)
- Edward Mathers IND (61)
- Niall O' Donnell IND (48)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 2nd, 2018
- Public Since
- July 18th, 2019
- No. of Shareholders
- 21
- No. of Employees
- 264
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 47,003,329
- Address
- 950 Tower Ln Ste 1050, FOSTER CITY, 94404-4251
- Web
- https://mirumpharma.com/
- Phone
- +1 6506674085
- Contact
- Andrew Mckibben
- Auditors
- Ernst & Young LLP
Upcoming Events for MIRM
Mirum Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Mirum Pharmaceuticals Inc Earnings Release
Similar to MIRM
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Mirum Pharmaceuticals share price?
As of Today at 19:14 UTC, shares in Mirum Pharmaceuticals are trading at $24.58. This share price information is delayed by 15 minutes.
How has the Mirum Pharmaceuticals share price performed this year?
Shares in Mirum Pharmaceuticals last closed at $24.58 and the price had moved by -0.85% over the past 365 days. In terms of relative price strength the Mirum Pharmaceuticals share price has underperformed the S&P500 Index by -19.92% over the past year.
What are the analyst and broker recommendations for Mirum Pharmaceuticals?
The overall consensus recommendation for Mirum Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mirum Pharmaceuticals dividend yield?
Mirum Pharmaceuticals does not currently pay a dividend.
Does Mirum Pharmaceuticals pay a dividend?
Mirum Pharmaceuticals does not currently pay a dividend.
When does Mirum Pharmaceuticals next pay dividends?
Mirum Pharmaceuticals does not currently pay a dividend.
How do I buy Mirum Pharmaceuticals shares?
To buy shares in Mirum Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mirum Pharmaceuticals?
As of the previous close price of $24.58, shares in Mirum Pharmaceuticals had a market capitalisation of $1.16bn.
Where are Mirum Pharmaceuticals shares listed?
Here are the trading details for Mirum Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: MIRM
What kind of share is Mirum Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Mirum Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mirum Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Mirum Pharmaceuticals is $49.00. That is 99.35% above the last closing price of $24.58.
Analysts covering Mirum Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.23 for the next financial year.
What is the trend in the Mirum Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mirum Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -25.38%.
As of the last closing price of $24.58, shares in Mirum Pharmaceuticals were trading -12.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mirum Pharmaceuticals PE Ratio?
The Mirum Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mirum Pharmaceuticals?
Mirum Pharmaceuticals' management team is headed by:
- Michael Grey - CHM
- Christopher Peetz - PRE
- Ian Clements - CFO
- Peter Radovich - COO
- Pamela Vig - CSO
- Lara Longpre - OTH
- Edwin Tucker - OTH
- Carol Brosgart - DRC
- William Fairey - DRC
- Laura Brege - IND
- Laurent Fischer - IND
- Patrick Heron - IND
- Edward Mathers - IND
- Niall O' Donnell - IND